IXICO announces an expansion of its pilot of the Assessa® PML platform which includes Biogen, a leading company in Multiple Sclerosis (“MS”), and expert reading institutions.
The Assessa® PML digital platform is being piloted in five EU countries as part of a collaborative agreement which was announced on 9 October 2015. The aim is to facilitate the remote transfer, management and storage of MRI scans to more reliably and effectively offer access to reading expertise for the detection of Progressive Multifocal Leukoencephalopathy (“PML”), a rare and potentially fatal disease that affects people living with MS. The pilot, which includes platform development and on-boarding of clinical sites participating in the pilot, has now been expanded to include pharmacovigilance reporting (monitoring the effects of medical drugs in order to identify and evaluate previously unreported adverse reactions).
The total contribution paid or to be paid to IXICO and its partners, associated with the scoping, development and pilot stages of this partnership, is in the order of £1.5m, of which £0.8m has been recognised from project inception to date. Subject to the timing of the work being performed, the fees payable to IXICO support the Company’s confidence in delivering revenue growth in the financial year ending 30 September 2017.